A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator

Neuroscience

Volumn 220, Issue , 2012, Pages 302-312

  Ishiguro, M ^a,b   Kawasaki, K ^c   Suzuki, Y ^a   Ishizuka, F ^a   Mishiro, K ^a   Egashira, Y ^b   Ikegaki, I ^c   Tsuruma, K ^a   Shimazawa, M ^a   Yoshimura, S ^b   Iwama, T ^b   Hara, H ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Blood brain barrier; Hemorrhagic infarction; MMP 9; Rho kinase inhibitor; TPA

Indexed keywords

FASUDIL; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BRAIN INFARCTION SIZE; BRAIN INJURY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HEMORRHAGIC TRANSFORMATION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MICROVASCULAR ENDOTHELIAL CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; PREVENTION; PRIORITY JOURNAL; RAT; REPERFUSION; TREATMENT RESPONSE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; PROTEIN KINASE INHIBITORS; RATS, SPRAGUE-DAWLEY; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84864748590     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.06.015     Document Type: Article

References (44)

1. Arai K., Jin G., Navaratna D., Lo E.H. Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J 2009, 276:4644-4652.
2. Ballabh P., Braun A., Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004, 16:1-13.
3. Breslin J.W., Yuan S.Y. Involvement of RhoA and Rho kinase in neutrophilstimulated endothelial hyperpermeability. Am J Physiol 2004, 286:1057-1062.
4. Hacke W., Kaste M., Bluhmki E., Brozman M., Dávalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D., Investigators E.C.A.S.S. Thrombolysis with alteplase 3 to 4.5h after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
5. Hara H., Huang P.L., Panahian N., Fishman M.C., Moskowitz M.A. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 1996, 16:605-611.
6. Hara H., Friedlander R.M., Gagliardini V., Ayata C., Fink K., Huang Z., Shimizu-Sasamata M., Yuan J., Moskowitz M.A. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997, 94:2007-2012.
7. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res 2003, 93:767-775.
8. Hitomi A., Satoh S., Ikegaki I., Suzuki Y., Shibuya M., Asano T. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci 2000, 67:1929-1939.
9. Ikegaki I., Satoh T., Sata M., Asano T. Effect of fasudil (AT-877), a protein kinase inhibitor, on clotting time and platelet aggregation. Jpn Pharmacol Ther 1996, 24:799-801.
10. Ishiguro M., Mishiro K., Fujiwara Y., Chen H., Izuta H., Tsuruma K., Shimazawa M., Yoshimura S., Satoh M., Iwama T., Hara H. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010, 5(12):6.
11. Janzer R.C., Raff M.C. Astrocytes induce bloodbrain barrier properties in endothelial cells. Nature 1987, 325:253-257.
12. Li Q., Huang X.J., He W., Ding J., Jia J.T., Fu G., Wang H.X., Guo L.J. Neuroprotective potential of fasudil mesylate in brain ischemia-reperfusion injury of rats. Cell Mol Neurobiol 2009, 29:169-180.
13. Marks M.P., Olivot J.M., Kemp S., Lansberg M.G., Bammer R., Wechsler L.R., Albers G.W., Thijs V. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology 2008, 249:614-623. DEFUSE investigators.
14. Nonaka Y., Koumura A., Hyakkoku K., Shimazawa M., Yoshimura S., Iwama T., Hara H. Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. J Pharmacol Exp Ther 2009, 330:13-22.
15. Qin Z., Karabiyikoglu M., Hua Y., Silbergleit R., He Y., Keep R.F., Xi G. Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia. Stroke 2007, 38:1362-1367.
16. Rieckmann P., Engelhardt B. Building up the blood-brain barrier. Nat Med 2003, 9:828-829.
17. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
18. Sahai E., Marshall C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002, 4:408-415.
19. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., Asano T. Inhibition of neutrophilmigration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 1999, 30:41-48.
20. Satoh S., Utsunomiya T., Tsurui K., Kobayashi K., Ikegaki I., Sasaki Y., Asano T. Pharmacological profile of hydroxyphasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 2001, 69:1441-1453.
21. Satoh S., Hitomi A., Ikegaki I., Kawasaki K., Nakazono O., Iwasaki M., Mohri M., Asano T. Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull 2010, 15:191-195.
22. Shibuya M., Suzuki Y., Sugita K., Saito I., Sasaki T., Takakura K., Nagata I., Kikuchi H., Takemae T., Hidaka H., Nakashima M. Effect of AT877 on cerebral vasospasm after aneurismal subarachnoid hemorrhage. J Neurosurg 1992, 76:571-577.
23. Shibuya M., Hirai S., Seto M., Satoh S., Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005, 238:31-39.
24. Simokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002, 39:319-327.
25. Sumii T., Lo E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002, 33:831-836.
26. Takemoto M., Sun J., Hiroki J., Shimokawa H., Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106:57-62.
27. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
28. Intracerebral hemorrhage after intravenous tPA therapy for ischemic stroke. Stroke 1997, 28:2109-2118. The NINDS rt-PA Stroke Study Group.
29. Thomalla G., Schwark C., Sobesky J., Bluhmki E., Fiebach J.B., Fiehler J., Zaro Weber O., Kucinski T., Juettler E., Ringleb P.A., Zeumer H., Weiller C., Hacke W., Schellinger P.D., Röther J. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006, 37:852-858. MRI in Acute Stroke Study Group of the German Competence Network Stroke.
30. Turner N.A., O'Regan D.J., Ball S.G., Porter K.E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005, 19:804-806.
31. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamaguchi K., Inui J., Maekawa M., Narumiya S. Calcium sensitization of smooth muscle mediated by Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
32. Valable S., Montaner J., Bellail A., Berezowski V., Brillault J., Cecchelli R., Divoux D., Mackenzie E.T., Bernaudin M., Roussel S., Petit E. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang1. J Cereb Blood Flow Metab 2005, 25:1491-1504.
33. Van Hinsbergh V.W., Van Nieuw Amerongen G.P. Intracellular signaling involved in modulating human endothelial barrier function. J Anat 2002, 200:549-560.
34. Walsh S.V., Hopkins A.M., Chen J., Narumiya S., Parkos C.A., Nusrat A. Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia. Gastroenterology 2001, 121:566-579.
35. Wang S., Lee S.R., Guo S.Z., Kim W.J., Montaner J., Wang X., Lo E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006, 37:1910-1912.
36. Willis C.L., Leach L., Clarke G.J., Nolan C.C., Ray D.E. Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia 2004, 48:1-13.
37. Wojciak-Stothard B., Ridley A.J. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 2002, 39:187-199.
38. Yagi K., Kitazato K.T., Uno M., Tada Y., Kinouchi T., Shimada K., Nagahiro S. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009, 40:626-631.
39. Yamashita K., Kotani Y., Nakajima Y., Shimazawa M., Yoshimura S., Nakashima S., Iwama T., Hara H. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007, 1154:215-224.
40. Yamashita T., Kamiya T., Deguchi K., Inaba T., Zhang H., Shang J., Miyazaki K., Ohtsuka A., Katayama Y., Abe K. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009, 29:715-725.
41. Yepes M., Sandkvist M., Moore E.G., Bugge T.H., Strickland D.K., Lawrence D.A. Tissuetype plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003, 112:1533-1540.
42. Zhang W., Sato K., Hayashi T., Omori N., Nagano I., Kato S., Horiuchi S., Abe K. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004, 26:342-348.
43. Zhao Y., Li Z., Wang R., Wei J., Li G., Zhao H. Angiopoietin 1 counteracts vascular endothelial growth factor-induced blood-brain barrier permeability and alleviates ischemic injury in the early stages of transient focal cerebral ischemia in rats. Neurol Res 2009, 32:748-755.
44. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.